Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Strata Critical Medical, Inc.SRTA · Entity 5512 | CEO, Clinical Services | September 08, 2026 | September 10, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Strata Critical Medical, Inc.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A common stock, $0.0001 par value per shareSEC Table I · non-derivative | Direct | 1,128,096 |
Reported balance
After 2026-09-08 transaction · row 1
1 source rowRow 1 · 2026-09-08 · Tax withholding · Disposed 5,697 · Balance 1,128,096 F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. |
| Class A common stock, $0.0001 par value per shareSEC Table I · non-derivative | IndirectSee Footnote | 132,232 |
Reported balance
Holding disclosure · report date 2026-09-08 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 132,232 F2: The reported securities are held by the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025 for which the Reporting Person serves as the trustee. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
F2: The reported securities are held by the LOUIS VERDETTO IRREVOCABLE TRUST DATED AUGUST 20 2025 for which the Reporting Person serves as the trustee.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 20:28 UTC | Strata Critical Medical, Inc. SRTA · Entity 5512 | Tax withholdingClass A common stock, $0.0001 par value per share | 5,697 | $5.31 | $30,251.07 |
DisclosureSEC source: 0001628280-26-061370 · wk-form4_1789072122.xml · nonDerivative · entry 1 Verdetto Louis R. · CIK 0002095962 · CEO, Clinical Services 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,128,096 F1 · shares: Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units. Read SEC document |
| December 02, 2025 Filed Dec 4, 2025 21:21 UTC | Strata Critical Medical, Inc. SRTA · Entity 5512 | GrantClass A common stock, $0.0001 par value per share | 63,918 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-055371 · wk-form4_1764883296.xml · nonDerivative · entry 1 Verdetto Louis R. · CIK 0002095962 · CEO Keystone Perfusion Service 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,133,793 F1 · shares: Represents a grant of Restricted Stock Units ("RSUs"), which will be settled in shares of the Issuer's common stock upon vesting: 25% of the RSUs (rounded down to the nearest whole number) to become vested on September 8, 2026 and then 6.25% (rounded down to the nearest whole number) will vest every 3 months thereafter, with any remaining unvested RSUs to vest on September 8, 2029, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.